• Je něco špatně v tomto záznamu ?

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

P. Moayyedi, JW. Eikelboom, J. Bosch, SJ. Connolly, L. Dyal, O. Shestakovska, D. Leong, SS. Anand, S. Störk, KRH. Branch, DL. Bhatt, PB. Verhamme, M. O'Donnell, AP. Maggioni, EM. Lonn, LS. Piegas, G. Ertl, M. Keltai, N. Cook Bruns, E. Muehlhofer,...

. 2019 ; 157 (2) : 403-412.e5. [pub] 20190502

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19034592

BACKGROUND & AIMS: Antiplatelets and anticoagulants are associated with increased upper gastrointestinal bleeding. We evaluated whether proton pump inhibitor therapy could reduce this risk. METHODS: We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants with stable cardiovascular disease and peripheral artery disease. Participants were randomly assigned to groups given pantoprazole 40 mg daily or placebo, as well as rivaroxaban 2.5 mg twice daily with aspirin 100 mg once daily, rivaroxaban 5 mg twice daily, or aspirin 100 mg alone. The primary outcome was time to first upper gastrointestinal event, defined as a composite of overt bleeding, upper gastrointestinal bleeding from a gastroduodenal lesion or of unknown origin, occult bleeding, symptomatic gastroduodenal ulcer or ≥5 erosions, upper gastrointestinal obstruction, or perforation. RESULTS: There was no significant difference in upper gastrointestinal events between the pantoprazole group (102 of 8791 events) and the placebo group (116 of 8807 events) (hazard ratio, 0.88; 95% confidence interval [CI], 0.67-1.15). Pantoprazole significantly reduced bleeding of gastroduodenal lesions (hazard ratio, 0.52; 95% confidence interval, 0.28-0.94; P = .03); this reduction was greater when we used a post-hoc definition of bleeding gastroduodenal lesion (hazard ratio, 0.45; 95% confidence interval, 0.27-0.74), although the number needed to treat still was high (n = 982; 95% confidence interval, 609-2528). CONCLUSIONS: In a randomized placebo-controlled trial, we found that routine use of proton pump inhibitors in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease does not reduce upper gastrointestinal events, but may reduce bleeding from gastroduodenal lesions. ClinicalTrials.gov ID: NCT01776424.

Amphia Ziekenhuis and Werkgroep Cardiologische Centra Nederland Utrecht the Netherlands

Bayer Leverkusen Germany

Brigham and Women's Hospital Heart and Vascular Center Harvard Medical School Boston Massachusetts

Cardiocenter University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University Prague Czech Republic

Catholic University of Korea Seoul South Korea

Centre for Cardiovascular Science University of Edinburgh Edinburgh UK

College of Medicine University of the Philippines Manila Ermita Manila Philippines

Collegium Medicum Jagiellonian University Krakow Poland

Estudios Clinicos Latino America and Instituto Cardiovascular de Rosario Rosario Argentina

Facultad de Ciencias de la Salud Eugenio Espejo Universidad Tecnoligica Equinoccial Quito Ecuador

FuWai Hospital Beijing China

Hopitaux de Paris Paris France

Hospital do Coracao Sao Paulo Brazil

Institut Universitaire de Cardiologie et de Pneumologie de Quebec Quebec Canada

Institute of Cardiology Kiev Ukraine

Instituto Dante Pazzanese de Cardiologia Sao Paulo Brazil

Karolinska Institutet Stockholm Sweden

Lady Davis Carmel Medical Center Haifa Israel

Monash University Melbourne Victoria Australia

National Association of Hospital Cardiologists Research Center Florence Italy

National Research Center for Preventative Medicine Moscow Russia

National University of Ireland Galway Ireland

Osaka International Cancer Institute Osaka Japan

Research Institute Fundaciun Oftalmoligica de Santander Bucaramanga Bucaramanga Colombia

Semmelweis University Budapest Hungary

The Population Health Research Institute McMaster University and Hamilton Health Sciences Hamilton Ontario Canada

Thrombosis Research Institute and University College London London UK

Turku University Central Hospital and Turku University Turku Finland

Universidad de La Frontera Temuco Chile

Universit Paris Diderot Hopital Bichat Assistance Publique Paris France

Universiti Teknologi Mara Selangor Malaysia

University of Aalborg Copenhagen Denmark

University of Cape Town Cape Town South Africa

University of Glasgow Glasgow UK

University of Leuven Leuven Belgium

University of Medicine and Pharmacology Carol Davila University and Emergency Hospital Bucharest Romania

University of Philippines Manila Philippines

University of Washington Medical Center Seattle Washington

University of Washington Seattle Washington

University of Würzburg and University Hospital Würzburg Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034592
003      
CZ-PrNML
005      
20200427140819.0
007      
ta
008      
191007s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1053/j.gastro.2019.04.041 $2 doi
035    __
$a (PubMed)31054846
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Moayyedi, Paul $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. Electronic address: moayyep@mcmaster.ca.
245    10
$a Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial / $c P. Moayyedi, JW. Eikelboom, J. Bosch, SJ. Connolly, L. Dyal, O. Shestakovska, D. Leong, SS. Anand, S. Störk, KRH. Branch, DL. Bhatt, PB. Verhamme, M. O'Donnell, AP. Maggioni, EM. Lonn, LS. Piegas, G. Ertl, M. Keltai, N. Cook Bruns, E. Muehlhofer, GR. Dagenais, JH. Kim, M. Hori, PG. Steg, RG. Hart, R. Diaz, M. Alings, P. Widimsky, A. Avezum, J. Probstfield, J. Zhu, Y. Liang, P. Lopez-Jaramillo, A. Kakkar, AN. Parkhomenko, L. Ryden, N. Pogosova, A. Dans, F. Lanas, PJ. Commerford, C. Torp-Pedersen, T. Guzik, D. Vinereanu, AM. Tonkin, BS. Lewis, C. Felix, K. Yusoff, K. Metsarinne, KAA. Fox, S. Yusuf, COMPASS Investigators,
520    9_
$a BACKGROUND & AIMS: Antiplatelets and anticoagulants are associated with increased upper gastrointestinal bleeding. We evaluated whether proton pump inhibitor therapy could reduce this risk. METHODS: We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants with stable cardiovascular disease and peripheral artery disease. Participants were randomly assigned to groups given pantoprazole 40 mg daily or placebo, as well as rivaroxaban 2.5 mg twice daily with aspirin 100 mg once daily, rivaroxaban 5 mg twice daily, or aspirin 100 mg alone. The primary outcome was time to first upper gastrointestinal event, defined as a composite of overt bleeding, upper gastrointestinal bleeding from a gastroduodenal lesion or of unknown origin, occult bleeding, symptomatic gastroduodenal ulcer or ≥5 erosions, upper gastrointestinal obstruction, or perforation. RESULTS: There was no significant difference in upper gastrointestinal events between the pantoprazole group (102 of 8791 events) and the placebo group (116 of 8807 events) (hazard ratio, 0.88; 95% confidence interval [CI], 0.67-1.15). Pantoprazole significantly reduced bleeding of gastroduodenal lesions (hazard ratio, 0.52; 95% confidence interval, 0.28-0.94; P = .03); this reduction was greater when we used a post-hoc definition of bleeding gastroduodenal lesion (hazard ratio, 0.45; 95% confidence interval, 0.27-0.74), although the number needed to treat still was high (n = 982; 95% confidence interval, 609-2528). CONCLUSIONS: In a randomized placebo-controlled trial, we found that routine use of proton pump inhibitors in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease does not reduce upper gastrointestinal events, but may reduce bleeding from gastroduodenal lesions. ClinicalTrials.gov ID: NCT01776424.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $7 D000925
650    _2
$a Aspirin $x aplikace a dávkování $x škodlivé účinky $7 D001241
650    _2
$a kardiovaskulární nemoci $x prevence a kontrola $7 D002318
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a kombinovaná farmakoterapie $x škodlivé účinky $x metody $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální krvácení $x chemicky indukované $x epidemiologie $x prevence a kontrola $7 D006471
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pantoprazol $x aplikace a dávkování $7 D000077402
650    _2
$a peptický vřed $x chemicky indukované $x epidemiologie $x prevence a kontrola $7 D010437
650    _2
$a inhibitory protonové pumpy $x aplikace a dávkování $7 D054328
650    _2
$a rivaroxaban $x aplikace a dávkování $x škodlivé účinky $7 D000069552
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Eikelboom, John W $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Bosch, Jackie $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Connolly, Stuart J $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Dyal, Leanne $u University of Philippines, Manila, Philippines.
700    1_
$a Shestakovska, Olga $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Leong, Darryl $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Anand, Sonia S $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Störk, Stefan $u University of Würzburg and University Hospital, Würzburg, Germany.
700    1_
$a Branch, Kelly R H $u University of Washington Medical Center, Seattle, Washington.
700    1_
$a Bhatt, Deepak L $u Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts.
700    1_
$a Verhamme, Peter B $u University of Leuven, Leuven, Belgium.
700    1_
$a O'Donnell, Martin $u National University of Ireland, Galway, Ireland.
700    1_
$a Maggioni, Aldo P $u National Association of Hospital Cardiologists Research Center (ANMCO), Florence, Italy.
700    1_
$a Lonn, Eva M $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada; Bayer, Leverkusen, Germany.
700    1_
$a Piegas, Leopoldo S $u Hospital do Coracao, Sao Paulo, Brazil.
700    1_
$a Ertl, Georg $u University of Würzburg and University Hospital, Würzburg, Germany.
700    1_
$a Keltai, Matyas $u Semmelweis University, Budapest, Hungary.
700    1_
$a Cook Bruns, Nancy $u Bayer, Leverkusen, Germany.
700    1_
$a Muehlhofer, Eva $u Bayer, Leverkusen, Germany.
700    1_
$a Dagenais, Gilles R $u Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada.
700    1_
$a Kim, Jae-Hyung $u Catholic University of Korea, Seoul, South Korea.
700    1_
$a Hori, M. $d 1945- $7 xx0247187 $u Osaka International Cancer Institute, Osaka, Japan.
700    1_
$a Steg, P Gabriel $u Hopitaux de Paris, Paris, France.
700    1_
$a Hart, Robert G $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Diaz, Rafael $u Estudios Clinicos Latino America and Instituto Cardiovascular de Rosario, Rosario, Argentina.
700    1_
$a Alings, Marco $u Amphia Ziekenhuis and Werkgroep Cardiologische Centra Nederland (WCN), Utrecht, the Netherlands.
700    1_
$a Widimsky, Petr $u Cardiocenter, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Avezum, Alvaro $u Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil.
700    1_
$a Probstfield, Jeffrey $u University of Washington, Seattle, Washington.
700    1_
$a Zhu, Jun $u FuWai Hospital, Beijing, China.
700    1_
$a Liang, Yan $u FuWai Hospital, Beijing, China.
700    1_
$a Lopez-Jaramillo, Patricio $u Research Institute, Fundaciun Oftalmoligica de Santander (FOSCAL)-Bucaramanga, Bucaramanga, Colombia.
700    1_
$a Kakkar, Ajay $u Thrombosis Research Institute and University College London, London, UK.
700    1_
$a Parkhomenko, Alexander N $u Institute of Cardiology, Kiev, Ukraine.
700    1_
$a Ryden, Lars $u Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Pogosova, Nana $u National Research Center for Preventative Medicine, Moscow, Russia.
700    1_
$a Dans, Antonio $u College of Medicine, University of the Philippines-Manila, Ermita, Manila, Philippines.
700    1_
$a Lanas, Fernando $u Universidad de La Frontera, Temuco, Chile.
700    1_
$a Commerford, Patrick J $u University of Cape Town, Cape Town, South Africa.
700    1_
$a Torp-Pedersen, Christian $u University of Aalborg, Copenhagen, Denmark.
700    1_
$a Guzik, Tomek $u University of Glasgow, Glasgow, UK; Collegium Medicum Jagiellonian University, Krakow, Poland.
700    1_
$a Vinereanu, Dragos $u University of Medicine and Pharmacology, Carol Davila University and Emergency Hospital, Bucharest, Romania.
700    1_
$a Tonkin, Andrew M $u Monash University, Melbourne, Victoria, Australia.
700    1_
$a Lewis, Basil S $u Lady Davis Carmel Medical Center, Haifa, Israel.
700    1_
$a Felix, Camilo $u Facultad de Ciencias de la Salud Eugenio Espejo-Universidad Tecnoligica Equinoccial, Quito, Ecuador.
700    1_
$a Yusoff, Khalid $u Universiti Teknologi Mara, Selangor, Malaysia.
700    1_
$a Metsarinne, Kaj $u Universit Paris Diderot, Hopital Bichat, Assistance Publique, Paris, France; Turku University Central Hospital and Turku University, Turku, Finland.
700    1_
$a Fox, Keith A A $u Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
700    1_
$a Yusuf, Salim $u The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
710    2_
$a COMPASS Investigators
773    0_
$w MED00001877 $t Gastroenterology $x 1528-0012 $g Roč. 157, č. 2 (2019), s. 403-412.e5
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31054846 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20200427140819 $b ABA008
999    __
$a ok $b bmc $g 1451252 $s 1073142
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 157 $c 2 $d 403-412.e5 $e 20190502 $i 1528-0012 $m Gastroenterology $n Gastroenterology $x MED00001877
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace